While strong cash generation is a hallmark of a healthy business, it's not the whole story. We analyze three companies with solid cash flow, highlighting one that reinvests for growth and two where underlying risks may outweigh the financial metrics.
A major grant from Centene's foundation aims to tackle housing insecurity for justice-involved individuals in Chicago, spotlighting the healthcare giant's community investments as its stock faces persistent headwinds.
The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
While CeoTronics AG's (FRA:CEK) recent earnings report failed to ignite its stock price, a deeper look reveals a robust cash conversion story that may please long-term shareholders and point to healthier fundamentals than the headline profit figure suggests.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
As diplomatic efforts to secure a ceasefire in Gaza show fragile progress, Israeli airstrikes have resulted in the deaths of at least 30 Palestinians overnight, with multiple children among the casualties, according to local health authorities.
Amidst global market volatility, a focused look at Asia reveals companies with resilient fundamentals trading at compelling valuations. We analyze three such names from the education, healthcare, and chemical sectors.
As regional markets navigate post-oil volatility and geopolitical shifts, a closer look reveals three penny stocks—from Turkish media to Saudi healthcare—that combine resilient balance sheets with high-risk, high-reward potential for the discerning investor.
As the ASX braces for a turbulent week amid rate hike fears, investors are scouring the market for resilient opportunities. We delve into three penny stocks—spanning energy, retail, and healthcare—that combine financial stability with distinct growth narratives for the discerning investor.
Health and Human Services Secretary Robert F. Kennedy Jr. has publicly addressed the deep divisions within America's most storied political family, following the death of his cousin Tatiana Schlossberg and amidst ongoing policy controversies that have placed him at odds with his relatives.
A 12-foot great white shark, tracked from Nova Scotia, has been detected in the Mississippi Sound, marking an unusual westward migration into the Gulf and offering clues about the region's marine health.
Following a bold earnings surprise, UPS is betting on a strategic pivot away from low-margin deliveries. While 2026 promises a challenging start, management forecasts a powerful second-half rebound fueled by cost cuts and a focus on healthcare and SMBs.
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.
In a significant move to bolster its healthcare services and retain staff, Walmart is creating thousands of new leadership positions and raising wages for pharmacy technicians across its U.S. stores.
Merck & Co. shifts its cancer drug development playbook, opting for targeted collaborations with Guardant Health and Eikon Therapeutics after walking away from a major acquisition. Analysts debate whether the stock's current price fully reflects its long-term pipeline potential.
Bank of America has revised its price target for consumer goods giant Kimberly-Clark downward, citing sector-wide valuation pressures, even as the company reports resilient earnings and advances its transformation into a broader health and wellness player.
Gatsby Chocolate, the 'healthy' indulgence that captivated Sharks and shoppers alike, has vanished from shelves. We trace its journey from a multi-million dollar deal that never closed to its quiet demise, exploring what went wrong for a once-promising brand.
New CMS reimbursement rates are pressuring Medicare Advantage profits, sending shares of Humana and CVS Health lower. We analyze whether the sell-off presents a buying opportunity for dividend investors or signals deeper structural challenges.
While market attention remains fixated on tech giants, the Russell 2000 index harbors promising, lesser-known companies. We examine three firms with distinct competitive advantages in environmental services, digital health, and private markets.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
